Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers
NANot yet recruitingINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
October 31, 2025
Primary Completion Date
February 28, 2027
Study Completion Date
February 28, 2027
Conditions
Alzheimer's DiseaseBiomarkersNon-invasive DiagnosisPhosphorylated Protein p-tau217
Interventions
OTHER
blood withdrawal
blood withdrawal
Trial Locations (1)
80090
CHRU Amiens, Amiens
All Listed Sponsors
lead
Centre Hospitalier Universitaire, Amiens
OTHER
NCT07071649 - Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers | Biotech Hunter | Biotech Hunter